marijuana stocks

Form 8-K for SURNA INC.


27-Feb-2015

Regulation FD Disclosure, Financial Statements and Exhibits

Item 7.01. Regulation FD Disclosure.Beginning on February 27, 2015, management of Surna Inc. will deliver to certain investors the presentation attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information included in this current report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this current report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01. Financial Statements and Exhibits.(d) Exhibits.

Exhibit No.   Description of Exhibit

   99.1       Investor presentation to be delivered by management of Surna Inc.
              beginning on February 27, 2015.

 

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Plandai Biotechnology Inc. (PLPL) Utilizes Green Tea to Fight Type 2 Diabetes

Plandai Biotechnology’s Phytofare® Utilizes Green Tea to Fight Type 2 Diabetes Plandai…

HEXO Corp (HEXO) to Participate in Alliance Global Partners 2021 Spring Consumer Cannabis Conference

HEXO Corp to Participate in Alliance Global Partners 2021 Spring Consumer Cannabis…

$MJNA A New Audio Interview with Dr. Stuart Titus

A New Audio Interview with Dr. Stuart Titus, President and Chief Executive…

$CMM Announces its intention to complete a 7,500 patient observational study in 2017.

 Canabo Medical Inc. (TSX VENTURE:CMM) (“Canabo” or the “Company”) today announces its…